Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most common type and composes about 90% of pancreatic cancer featured with high intra-tumoral heterogeneity and poor prognosis, which has been considered the least immunogenic cancer for decades. However, this characterization might be over-simplistic, and more sophisticated approaches are needed to develop effective treatment strategies. In this review, we aim to summarize studies involving PDAC immunity in different aspects to provide a multidimensional recognition and comprehensively understanding of the mechanisms underlying the tumor microenvironment (TME) of PDAC. A database search of peer-reviewed articles published in English between 2003 and 2022 in PubMed and the Web of Science was performed. Original articles and review articles relevant to the topic were selected. We emphasized the importance of investigating tumor-infiltrating lymphocytes (TILs) in pancreatic cancer, especially focusing on CD8+ T cells, along with indicating potential therapeutic strategies to turn the immune-cold PDACs into the immune-hot ones.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
